Target Information

Target General Information

Top

Target ID

T86836 (Former ID: TTDI01911)

Target Name

Human Deoxyribonucleic acid (hDNA)

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 21 Target-related Diseases

Acute myeloid leukaemia [ICD-11: 2A60]

Brain cancer [ICD-11: 2A00]

Breast cancer [ICD-11: 2C60-2C6Y]

Colorectal cancer [ICD-11: 2B91]

Cystic fibrosis [ICD-11: CA25]

Hodgkin lymphoma [ICD-11: 2B30]

Kaposi sarcoma [ICD-11: 2B57]

Leukaemia [ICD-11: 2A60-2B33]

Liver cancer [ICD-11: 2C12]

Lung cancer [ICD-11: 2C25]

Malignant digestive organ neoplasm [ICD-11: 2C11]

Mature T-cell lymphoma [ICD-11: 2A90]

Melanoma [ICD-11: 2C30]

Multiple myeloma [ICD-11: 2A83]

Myelodysplastic syndrome [ICD-11: 2A37]

Myeloproliferative neoplasm [ICD-11: 2A20]

Nutritional deficiency [ICD-11: 5B50-5B71]

Ovarian cancer [ICD-11: 2C73]

Pancreatic cancer [ICD-11: 2C10]

Prostate cancer [ICD-11: 2C82]

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 33 Approved Drugs

Adenine

Drug Info

Approved

Malnutrition

[2], [3]

Altretamine

Drug Info

Approved

Ovarian cancer

[4], [5]

Bendamustine hydrochloride

Drug Info

Approved

leukaemia

[6]

Bleomycin

Drug Info

Approved

Hodgkin lymphoma

[7]

Busulfan

Drug Info

Approved

Myeloproliferative syndrome

[8], [9]

Carboplatin

Drug Info

Approved

Ovarian cancer

[10], [11]

Cisplatin

Drug Info

Approved

Solid tumour/cancer

[12], [13]

Cyclophosphamide

Drug Info

Approved

Solid tumour/cancer

[14], [15]

Dacarbazine

Drug Info

Approved

Melanoma

[16]

Dactinomycin

Drug Info

Approved

Solid tumour/cancer

[17]

Daunorubicin

Drug Info

Approved

Acute myeloid leukaemia

[7], [18]

Decitabine

Drug Info

Approved

Myelodysplastic syndrome

[19], [20], [21]

Dornase Alfa

Drug Info

Approved

Cystic fibrosis

[7]

DTI-015

Drug Info

Approved

Liver cancer

[1]

Ifosfamide

Drug Info

Approved

Solid tumour/cancer

[22], [23]

Lomustine

Drug Info

Approved

Brain cancer

[21], [24], [25]

Lurbinectedin

Drug Info

Approved

Small-cell lung cancer

[26]

Mechlorethamine

Drug Info

Approved

T-cell lymphoma

[21]

Melphalan

Drug Info

Approved

Multiple myeloma

[27], [28]

Melphalan flufenamide

Drug Info

Approved

Multiple myeloma

[29]

Mitomycin

Drug Info

Approved

Breast cancer

[30], [7]

Mitomycin A

Drug Info

Approved

Solid tumour/cancer

[7]

Neocarzinostatin

Drug Info

Approved

Solid tumour/cancer

[21]

Oxaliplatin

Drug Info

Approved

Colorectal cancer

[31], [32]

Pipobroman

Drug Info

Approved

Refractory chronic myeloid leukaemia

[21], [33], [34]

Pirarubicin

Drug Info

Approved

Breast cancer

[21], [35]

Procarbazine

Drug Info

Approved

Hodgkin lymphoma

[36], [37]

Radium-223-Dichloride

Drug Info

Approved

Prostate cancer

[38]

Streptozocin

Drug Info

Approved

Pancreatic cancer

[7]

Temozolomide

Drug Info

Approved

Grade IV astrocytoma

[39], [7]

Uracil mustard

Drug Info

Approved

Acute myeloid leukaemia

[7], [21], [40]

Zinostatin stimalamer

Drug Info

Approved

Brain cancer

[21]

Dicycloplatin

Drug Info

Registered

Prostate cancer

[41]

Clinical Trial Drug(s)

[+] 42 Clinical Trial Drugs

Apaziquone

Drug Info

Phase 3

Non-muscle invasive bladder cancer

[42]

Glufosfamide

Drug Info

Phase 3

Pancreatic cancer

[43]

Laromustine

Drug Info

Phase 3

Solid tumour/cancer

[44]

Pafuramidine

Drug Info

Phase 3

Malaria

[45]

Taxol/Paraplatin/Herceptin

Drug Info

Phase 3

Breast cancer

[46]

VAL-083

Drug Info

Phase 3

Recurrent glioblastoma

[47]

13-DEOXYADRIAMYCIN HYDROCHLORIDE

Drug Info

Phase 2

Solid tumour/cancer

[48]

CGC-11047

Drug Info

Phase 2

Prostate cancer

[49]

CO-101

Drug Info

Phase 2

Pancreatic cancer

[50]

CYSTEMUSTINE

Drug Info

Phase 2

Solid tumour/cancer

[51]

DM-CHOC-PEN

Drug Info

Phase 2

Brain cancer

[52]

FAD-104

Drug Info

Phase 2

Solid tumour/cancer

[53]

JM216

Drug Info

Phase 2

Solid tumour/cancer

[54]

LADIRUBICIN

Drug Info

Phase 2

Breast cancer

[55]

NDDP

Drug Info

Phase 2

Solid tumour/cancer

[56]

NHS-IL2-LT

Drug Info

Phase 2

Solid tumour/cancer

[57]

OBI-3424

Drug Info

Phase 2

Acute lymphoblastic leukaemia

[58]

PM-00104

Drug Info

Phase 2

Solid tumour/cancer

[59]

TETRAPLATIN TETRANITRATE

Drug Info

Phase 2

Solid tumour/cancer

[60]

TH-302

Drug Info

Phase 2

Soft tissue sarcoma

[61], [62]

TOL-3021

Drug Info

Phase 2

leukaemia

[63]

TROXACITABINE

Drug Info

Phase 2

Solid tumour/cancer

[64]

BN-2629

Drug Info

Phase 1/2

Solid tumour/cancer

[65]

GTU-TB vaccine

Drug Info

Phase 1/2

Mycobacterium infection

[66]

MBO7133

Drug Info

Phase 1/2

Liver cancer

[67]

SECTA belomycin

Drug Info

Phase 1/2

Solid tumour/cancer

[68]

5-FP

Drug Info

Phase 1

Solid tumour/cancer

[69]

BIZELESIN

Drug Info

Phase 1

Skin disease

[70]

DABIS MALEATE

Drug Info

Phase 1

Solid tumour/cancer

[71]

DFP-14927

Drug Info

Phase 1

Solid tumour/cancer

[72]

FFC-14A

Drug Info

Phase 1

Solid tumour/cancer

[73]

GALAMUSTINE HYDROCHLORIDE

Drug Info

Phase 1

Solid tumour/cancer

[74]

INO-3401

Drug Info

Phase 1

Influenza A virus H5N1 infection

[75]

INO-3510

Drug Info

Phase 1

Influenza A virus H1N1/H5N1 infection

[75]

LY-2334737

Drug Info

Phase 1

Solid tumour/cancer

[76]

NC-4016

Drug Info

Phase 1

Solid tumour/cancer

[77]

PENCLOMEDINE

Drug Info

Phase 1

Solid tumour/cancer

[78]

Pennvax-B

Drug Info

Phase 1

Human immunodeficiency virus infection

[79]

Pennvax-G

Drug Info

Phase 1

Human immunodeficiency virus infection

[80]

RH 1

Drug Info

Phase 1

Discovery agent

[81]

T-0128

Drug Info

Phase 1

Solid tumour/cancer

[82]

Thiarabine

Drug Info

Phase 1

Solid tumour/cancer

[83]

Discontinued Drug(s)

[+] 24 Discontinued Drugs

Abetimus sodium

Drug Info

Discontinued in Phase 3

Lupus

[84]

ARANOSE

Drug Info

Discontinued in Phase 3

Solid tumour/cancer

[85]

KW-2149

Drug Info

Discontinued in Phase 3

Solid tumour/cancer

[86]

ADOZELESIN

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[87]

AP-5346

Drug Info

Discontinued in Phase 2

Head and neck cancer

[88]

BBR-3438

Drug Info

Discontinued in Phase 2

Gastric adenocarcinoma

[89]

BISNAFIDE MESILATE

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[90]

CARZELESIN

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[91]

NB-506

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[92]

PIBROZELESIN HYDROCHLORIDE

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[93]

Tallimustine

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[94]

TOPIXANTRONE HYDROCHLORIDE

Drug Info

Discontinued in Phase 2

Gastric adenocarcinoma

[95]

TV-4710

Drug Info

Discontinued in Phase 2

Systemic lupus erythematosus

[84]

Clomet

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[96]

FK-973

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[97]

PLD-147

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[98]

RB-6145

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[99]

S-23906-1

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[100]

SR-271425

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[101]

SW-33377

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[102]

ZD-2767

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[103]

Bisbenzimide (Hoechst 33258)

Drug Info

Terminated

Solid tumour/cancer

[105]

BW-A502U

Drug Info

Terminated

Solid tumour/cancer

[106]

Doxorubicin-CEA conjugate

Drug Info

Terminated

Breast cancer

[107]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

Indol-3-carbinol

Drug Info

Preclinical

Fungal infection

[104]

Mode of Action

[+] 7 Modes of Action

Binder

[+] 35 Binder drugs

Adenine

Drug Info

[108], [109]

DTI-015

Drug Info

[1]

Melphalan flufenamide

Drug Info

[29]

Mitomycin

Drug Info

[118], [125]

Pipobroman

Drug Info

[128]

Laromustine

Drug Info

[136]

Taxol/Paraplatin/Herceptin

Drug Info

[46]

CYSTEMUSTINE

Drug Info

[142]

FAD-104

Drug Info

[144]

LADIRUBICIN

Drug Info

[145]

NDDP

Drug Info

[146]

TETRAPLATIN TETRANITRATE

Drug Info

[149]

TROXACITABINE

Drug Info

[152]

BN-2629

Drug Info

[153]

MBO7133

Drug Info

[155]

SECTA belomycin

Drug Info

[156]

5-FP

Drug Info

[157]

DABIS MALEATE

Drug Info

[159]

FFC-14A

Drug Info

[161]

ARANOSE

Drug Info

[172]

KW-2149

Drug Info

[173]

ADOZELESIN

Drug Info

[158]

BBR-3438

Drug Info

[175]

CARZELESIN

Drug Info

[177]

PIBROZELESIN HYDROCHLORIDE

Drug Info

[179]

FK-973

Drug Info

[183]

PLD-147

Drug Info

[184]

RB-6145

Drug Info

[185]

S-23906-1

Drug Info

[186]

SR-271425

Drug Info

[187]

SW-33377

Drug Info

[188]

ZD-2767

Drug Info

[189]

Indol-3-carbinol

Drug Info

[104]

BW-A502U

Drug Info

[191]

AMBAZONE

Drug Info

[193]

Breaker

[+] 8 Breaker drugs

Altretamine

Drug Info

[110]

Bleomycin

Drug Info

[111]

Dacarbazine

Drug Info

[117]

Dactinomycin

Drug Info

[118]

Dornase Alfa

Drug Info

[120]

Streptozocin

Drug Info

[130]

Talisomycin

Drug Info

[111]

Nitracrine

Drug Info

[195]

Modulator

[+] 34 Modulator drugs

Bendamustine hydrochloride

Drug Info

[6]

Busulfan

Drug Info

[112]

Carboplatin

Drug Info

[113]

Cisplatin

Drug Info

[114]

Cyclophosphamide

Drug Info

[115], [116]

Decitabine

Drug Info

[20]

Ifosfamide

Drug Info

[121]

Melphalan

Drug Info

[124]

Neocarzinostatin

Drug Info

[7]

Oxaliplatin

Drug Info

[127]

Pirarubicin

Drug Info

[7]

Radium-223-Dichloride

Drug Info

[38]

Temozolomide

Drug Info

[131]

Uracil mustard

Drug Info

[132]

Zinostatin stimalamer

Drug Info

[7]

Apaziquone

Drug Info

[134]

Glufosfamide

Drug Info

[135]

Pafuramidine

Drug Info

[137]

VAL-083

Drug Info

[138]

13-DEOXYADRIAMYCIN HYDROCHLORIDE

Drug Info

[139]

CGC-11047

Drug Info

[140]

DM-CHOC-PEN

Drug Info

[143]

JM216

Drug Info

[139]

NHS-IL2-LT

Drug Info

[139]

PM-00104

Drug Info

[148]

TH-302

Drug Info

[150]

TOL-3021

Drug Info

[151]

LY-2334737

Drug Info

[165], [166]

PENCLOMEDINE

Drug Info

[168]

RH 1

Drug Info

[81]

Tallimustine

Drug Info

[180]

Doxorubicin-CEA conjugate

Drug Info

[131]

doxorubicin-LL2 conjugate

Drug Info

[194]

doxorubicin-peptide-PEG conjugate

Drug Info

[194]

Intercalator

[+] 3 Intercalator drugs

Daunorubicin

Drug Info

[119]

Mechlorethamine

Drug Info

[123]

Ethidium

Drug Info

[119]

Inhibitor

[+] 21 Inhibitor drugs

Lomustine

Drug Info

[122]

Lurbinectedin

Drug Info

[26]

Dicycloplatin

Drug Info

[133]

CO-101

Drug Info

[141]

BIZELESIN

Drug Info

[158]

DFP-14927

Drug Info

[160]

NC-4016

Drug Info

[167]

T-0128

Drug Info

[170]

Thiarabine

Drug Info

[171]

Abetimus sodium

Drug Info

[84]

AP-5346

Drug Info

[174]

BISNAFIDE MESILATE

Drug Info

[176]

NB-506

Drug Info

[178]

TOPIXANTRONE HYDROCHLORIDE

Drug Info

[181]

TV-4710

Drug Info

[84]

Clomet

Drug Info

[182]

2-(3,4-Dihydroxyphenyl)Acetic Acid

Drug Info

[192]

alphabeta-methyleneADP

Drug Info

[192]

Beta-D-Glucose

Drug Info

[192]

Lipid Fragment

Drug Info

[192]

Thiamin Diphosphate

Drug Info

[192]

Antagonist

[+] 1 Antagonist drugs

GALAMUSTINE HYDROCHLORIDE

Drug Info

[162]

Binder (minor groove binder)

[+] 1 Binder (minor groove binder) drugs

Bisbenzimide (Hoechst 33258)

Drug Info

[190]

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

References

Top

REF 1

Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.

REF 2

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4788).

REF 3

Drug information of Adenine, 2008. eduDrugs.

REF 4

REF 5

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019926.

REF 6

2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.

REF 7

Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.

REF 8

REF 9

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020954.

REF 10

REF 11

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076039.

REF 12

REF 13

Using the zebrafish lateral line to screen for ototoxicity. J Assoc Res Otolaryngol. 2008 Jun;9(2):178-90.

REF 14

REF 15

Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.

REF 16

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075259.

REF 17

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050682.

REF 18

REF 19

REF 20

2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.

REF 21

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 22

REF 23

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076078.

REF 24

REF 25

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017588.

REF 26

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020

REF 27

REF 28

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 014691.

REF 29

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021

REF 30

REF 31

REF 32

The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2009 May;36(5):797-801.

REF 33

REF 34

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016245.

REF 35

ClinicalTrials.gov (NCT01746992) CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma. U.S. National Institutes of Health.

REF 36

REF 37

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016785.

REF 38

Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.

REF 39

REF 40

REF 41

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031375)

REF 42

ClinicalTrials.gov (NCT00598806) Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant for Noninvasive Bladder Cancer. U.S. National Institutes of Health.

REF 43

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 44

ClinicalTrials.gov (NCT00112554) Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia. U.S. National Institutes of Health.

REF 45

ClinicalTrials.gov (NCT00302341) DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP). U.S. National Institutes of Health.

REF 46

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.

REF 47

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 48

ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health.

REF 49

ClinicalTrials.gov (NCT00585416) Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.

REF 50

ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.

REF 51

Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer. 1998 Feb;34(3):422-3.

REF 52

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029242)

REF 53

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000888)

REF 54

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol. 1999 Dec;17(12):3822-7.

REF 55

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15.

REF 56

ClinicalTrials.gov (NCT00004033) Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma. U.S. National Institutes of Health.

REF 57

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026542)

REF 58

ClinicalTrials.gov (NCT04315324) Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL). U.S. National Institutes of Health.

REF 59

ClinicalTrials.gov (NCT00900562) Clinical Trial of PM00104 (Zalypsis) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy. U.S. National Institutes of Health.

REF 60

ClinicalTrials.gov (NCT00014547) BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment. U.S. National Institutes of Health.

REF 61

REF 62

ClinicalTrials.gov (NCT01403610) Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab. U.S. National Institutes of Health.

REF 63

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019680)

REF 64

ClinicalTrials.gov (NCT00129948) Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.

REF 65

ClinicalTrials.gov (NCT02034227) Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia. U.S. National Institutes of Health.

REF 66

Clinical pipeline report, company report or official report of FIT Biotech.

REF 67

Clinical pipeline report, company report or official report of Metabasis Therapeutics (2006).

REF 68

Clinical pipeline report, company report or official report of Inovio.

REF 69

Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem. 1991 Nov;34(11):3280-4.

REF 70

ClinicalTrials.gov (NCT00003021) Bizelesin in Treating Patients With Advanced Cancer. U.S. National Institutes of Health.

REF 71

Phase I study of DABIS maleate given once every 3 weeks. Eur J Cancer. 1991;27(12):1635-7.

REF 72

ClinicalTrials.gov (NCT03943004) Trial of DFP-14927 in Advanced Solid Tumors. U.S. National Institutes of Health.

REF 73

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004610)

REF 74

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002476)

REF 75

ClinicalTrials.gov (NCT01405885) A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus. U.S. National Institutes of Health.

REF 76

ClinicalTrials.gov (NCT01648764) A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread. U.S. National Institutes of Health.

REF 77

ClinicalTrials.gov (NCT01999491) A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma. U.S. National Institutes of Health.

REF 78

ClinicalTrials.gov (NCT00002946) Penclomedine in Treating Patients With Solid Tumors or Lymphoma. U.S. National Institutes of Health.

REF 79

ClinicalTrials.gov (NCT00775424) PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection. U.S. National Institutes of Health.

REF 80

ClinicalTrials.gov (NCT01260727) Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults. U.S. National Institutes ofHealth.

REF 81

Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent RH1

REF 82

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014468)

REF 83

ClinicalTrials.gov (NCT01139151) 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies. U.S. National Institutes of Health.

REF 84

Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65.

REF 85

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004282)

REF 86

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002474)

REF 87

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000874)

REF 88

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017581)

REF 89

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)

REF 90

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003889)

REF 91

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001664)

REF 92

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005106)

REF 93

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003110)

REF 94

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001279)

REF 95

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)

REF 96

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011175)

REF 97

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000815)

REF 98

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018371)

REF 99

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002473)

REF 100

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016219)

REF 101

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011907)

REF 102

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003155)

REF 103

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004376)

REF 104

Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.

REF 105

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001915)

REF 106

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004913)

REF 107

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194)

REF 108

Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410.

REF 109

Leishmania donovani singly deficient in HGPRT, APRT or XPRT are viable in vitro and within mammalian macrophages. Mol Biochem Parasitol. 2006 Jul;148(1):24-30.

REF 110

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.

REF 111

Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.

REF 112

DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.

REF 113

Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.

REF 114

Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.

REF 115

O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.

REF 116

Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 1986 Oct;46(10):5029-34.

REF 117

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.

REF 118

Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.

REF 119

31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.

REF 120

Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45.

REF 121

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.

REF 122

Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33.

REF 123

Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62.

REF 124

Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.

REF 125

Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.

REF 126

Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42.

REF 127

Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.

REF 128

Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12.

REF 129

Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.

REF 130

Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90.

REF 131

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

REF 132

Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.

REF 133

Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63.

REF 134

EO9 (Apaziquone): from the clinic to the laboratory and back again

REF 135

A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33.

REF 136

Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6.

REF 137

DNA Minor Groove Induced Dimerization of Heterocyclic Cations: Compound Structure, Binding Affinity and Specificity for a TTAA Site

REF 138

Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3.

REF 139

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

REF 140

Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.

REF 141

Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.

REF 142

A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther. 2008 Jul;326(1):171-7.

REF 143

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 September; 64(4): 829-835.

REF 144

Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo). 1990 May;43(5):556-65.

REF 145

The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81.

REF 146

Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Anticancer Res. 1994 Mar-Apr;14(2A):421-6.

REF 147

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503.

REF 148

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011 May;96(5):687-95.

REF 149

Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251-8.

REF 150

Company report (Threshold Pharmaceuticals)

REF 151

Clinical pipeline report, company report or official report of Tolerion.

REF 152

Troxacitabine. Bull Cancer. 2004 Mar;91(3):213-8.

REF 153

Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226.

REF 154

Clinical pipeline report, company report or official report of hightechfinland.

REF 155

Novel Cox-2 Inhibitor for Breast Cancer Therapy. Temple University School of Medicine Philadelphia, Pennsylvania 19140. July 2004.

REF 156

Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13.

REF 157

Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003 Apr;9(4):1235-9.

REF 158

Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30.

REF 159

DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9.

REF 160

National Cancer Institute Drug Dictionary (drug name DFP14927).

REF 161

The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21.

REF 162

6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Cancer Res. 1987 Feb 1;47(3):696-9.

REF 163

ClinicalTrials.gov (NCT01403155) A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001. U.S. National Institutes of Health.

REF 164

Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine. Inovio. March 26, 2012.

REF 165

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.

REF 166

Role of gemcitabine in cancer therapy.Future Oncol.2005 Feb;1(1):7-17.

REF 167

Effects of Treatment with Platinum Azidothymidine and Azidothymidine on Telomerase Activity and Bcl-2 Concentration in Hepatocellular Carcinoma- Induced Rats. Avicenna J Med Biotechnol. 2014 Oct-Dec;6(4): 200-209.

REF 168

The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Invest New Drugs. 2003 Aug;21(3):269-79.

REF 169

Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601.

REF 170

Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95.

REF 171

Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem Rev. 2009 July; 109(7): 2880-2893.

REF 172

Alternative DNA loops regulate the arabinose operon in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5444-8.

REF 173

KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation. Biochem Pharmacol. 1998 Jun 1;55(11):1777-83.

REF 174

Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54.

REF 175

A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology. 2001;61(3):234-42.

REF 176

DNA sequence recognition by bispyrazinonaphthalimides antitumor agents. Biochemistry. 2003 Oct 14;42(40):11751-61.

REF 177

Sequence selectivity of DNA alkylation by adozelesin and carzelesin. Arch Pharm Res. 1998 Aug;21(4):385-90.

REF 178

DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107.

REF 179

Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer. 2007;38(1):10-4.

REF 180

Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des. 1998 Apr;13(3):193-205.

REF 181

Clinical pipeline report, company report or official report of CTI BioPharma.

REF 182

The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 2006;314:275-86.

REF 183

Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells. Jpn J Pharmacol. 1990 Aug;53(4):463-72.

REF 184

The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol Cancer. 2010 Jun 15;9:147.

REF 185

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.. Br J Cancer. 1995 March; 71(3): 537-542.

REF 186

Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol. 2001 Dec;60(6):1383-91.

REF 187

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol. 2009 Feb;32(1):9-14.

REF 188

Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells. Invest New Drugs. 1998-1999;16(3):221-5.

REF 189

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br J Cancer. 2001 September; 85(5): 764-771.

REF 190

Sequence-dependent effects in drug-DNA interaction: the crystal structure of Hoechst 33258 bound to the d(CGCAAATTTGCG)2 duplex. Nucleic Acids Res. 1994 May 11;22(9):1607-12.

REF 191

Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Drug Metab Dispos. 1993 Jan-Feb;21(1):62-70.

REF 192

How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

REF 193

Ambazone as a membrane active antitumor drug. Biophys Chem. 1990 Apr;35(2-3):287-300.

REF 194

The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.

REF 195

Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives. Neoplasma. 1999;46(1):50-3.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN